NEW YORK (GenomeWeb News) – Agendia is partnering with the University of Texas MD Anderson Cancer Center and the Netherlands Cancer Institute to use genomics and proteomics to better understand the biology of colorectal cancer, the Dutch firm announced today.
The research will combine several genomic and proteomic technologies to study gene and protein expression patterns in cancerous tumors, an approach that may result in greater insight into the biology of a patient's tumor and the reasoning behind different patient prognoses and patient responses, Agendia said.
The goal is to improve diagnosis and treatment options for colorectal cancer.
Past researchers have investigated just one aspect of the progression of colorectal cancer. The integrated approach being taken by the partners will analyze cancer samples on multiple levels with gene expression, mutation status, and protein activation measurements being combined with pathological results and clinical data, Agendia said.
Financial and other terms of the collaboration were not disclosed.
The deal also provides Agendia, which recently filed to go public in Europe, an independent validation of its ColoPrint colon cancer recurrence test currently under development. The test stratifies Stage II colon cancer patients as having either low or high risk for disease recurrence. Each year more than 1.2 million new cases of colon cancer are diagnosed.